- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
NCPA outraged at low reimbursement for generic Zocor
Complaints from NCPA members have been steadily building over low maximum allowable cost (MAC) reimbursement from Express Scripts for generic Zocor. According to NCPA, it has received numerous reports that Express Scripts, one of the largest PBMs in the country, has set a MAC for simvastatin at approximately two-thirds of the pharmacy acquisition price.
NCPA outraged at low reimbursement for generic Zocor
Complaints from NCPA members have been steadily building over low maximum allowable cost (MAC) reimbursement from Express Scripts for generic Zocor. According to NCPA, it has received numerous reports that Express Scripts, one of the largest PBMs in the country, has set a MAC for simvastatin at approximately two-thirds of the pharmacy acquisition price. The association has also reported that other PBMs may be following suit. NCPA has met with members of Congress in an effort to correct what it called "an abusive practice." On a related note, the association reported that some PBMs have moved Zocor into a tier-one or generic co-pay category, reimbursing pharmacies at the generic rate even though the plan is requiring that Zocor, a brand drug, be dispensed.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Implementing Interpersonal Care Model for PPHTN Can Help Manage Blood Pressure Control
December 5th 2023A poster presented at ASHP Midyear 2023 highlighted the positive impact of including pharmacists in the care of postpartum women at risk of persistently elevated blood pressure (BP), particularly in cases of portopulmonary hypertension (PPHTN).
Instagram Could Serve as Educational Platform for New FDA Drug Approvals
December 4th 2023An evaluative study on an open resource Instagram page that provides information on new medications to pharmacists was recently presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition.
